NCT04943575

Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 360 (actual)
• Sponsor: PPC Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

A randomized-controlled interventional clinical trial to evaluate the effectiveness of EZC Pak \& EZC Pak+D for the treatment of the common cold and/or a URI.

Detailed description

This is a randomized-controlled interventional treatment study with three arms of comparable demographics to evaluate the efficacy of PPC Pharmaceuticals EZC Pak (\& EZC Pak+D) to improve the severity and duration of the common cold or a URI in individuals. It is hypothesized that study participants will experience a positive impact on the duration and severity of their cold/URI while using EZC Pak (\&EZC Pak+D). The second study objective is to examine if patients are accepting the test product as an alternative to antibiotics.

Conditions

• Common Cold

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	EZC Pak	After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
DIETARY_SUPPLEMENT	EZC Pak +D	After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
DIETARY_SUPPLEMENT	Placebo	After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.

Timeline

• Start date: 2021-06-01
• Primary completion: 2022-01-30
• Completion: 2022-01-30
• First posted: 2021-06-29
• Last updated: 2022-04-07

Locations

1 site across 1 country: United States